How many 8-K filings has Rallybio Corp filed?

Rallybio Corp (RLYB) has 13 8-K (Current Event Report) filings on record, spanning Feb 2024 to May 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Rallybio Corp 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Rallybio Corp 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Rallybio Corp (RLYB) — 8-K Filings

All 8-K filings from Rallybio Corp. Browse 13 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (13)

8-K Filing — May 4, 2026
Rallybio Corp Faces Delisting Concerns — Aug 29, 2025 Risk: high
Rallybio Corporation filed an 8-K on August 29, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing ind
Rallybio Corp Completes Acquisition — Jul 8, 2025 Risk: medium
On July 8, 2025, Rallybio Corporation filed an 8-K to report the completion of an acquisition. The filing indicates the company entered into a material definiti
Rallybio Corp: Director Changes and Executive Compensation Update — Jun 27, 2025 Risk: low
Rallybio Corporation announced on June 25, 2025, the departure of Director David M. Gryska and the election of new Director Sarah E. P. Johnson. The company als
Rallybio Corp Files 8-K on Shareholder Vote — May 16, 2025 Risk: medium
Rallybio Corporation filed an 8-K on May 16, 2025, reporting on a matter submitted to a vote of its security holders on May 13, 2025. The filing does not disclo
Rallybio Corp Files 8-K with Financial Statements — Apr 8, 2025 Risk: low
On April 8, 2025, Rallybio Corporation filed an 8-K report. The filing primarily concerns the submission of financial statements and exhibits, indicating routin
Rallybio Corp Files 8-K Report — Mar 13, 2025 Risk: low
On March 13, 2025, Rallybio Corporation filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating up
Rallybio Faces Nasdaq Delisting Warning — Feb 25, 2025 Risk: high
Rallybio Corporation announced on February 24, 2025, that it received a notice from the Nasdaq Stock Market indicating a failure to meet a continued listing rul
Rallybio Names New Chief Medical Officer — Sep 17, 2024 Risk: medium
Rallybio Corporation announced on September 16, 2024, the departure of its Chief Medical Officer, Dr. Jeffrey M. Chiodo, effective September 13, 2024. The compa
Rallybio Corp Files 8-K on Executive and Board Changes — Jul 23, 2024 Risk: low
Rallybio Corporation filed an 8-K on July 23, 2024, reporting on the departure of directors or certain officers, election of directors, appointment of certain o
Rallybio Corp Files 8-K on Shareholder Matters — May 21, 2024 Risk: low
Rallybio Corporation filed an 8-K on May 21, 2024, reporting on matters submitted to a vote of security holders on May 15, 2024. The filing details the company'
Rallybio Corp Files 8-K: Material Agreement & Equity Sales — Apr 10, 2024 Risk: medium
Rallybio Corporation announced on April 9, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity s
Rallybio Files 8-K on Operations, Exit Costs — Feb 6, 2024
Rallybio Corp. filed an 8-K on February 6, 2024, indicating a current report regarding 'Results of Operations and Financial Condition' and 'Cost Associated with

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX